Refine
Year of publication
Document Type
- Article (33)
- Part of a Book (1)
- Doctoral Thesis (1)
- Preprint (1)
Has Fulltext
- yes (36)
Is part of the Bibliography
- no (36)
Keywords
- Epilepsy (2)
- Genetics (2)
- MLL (2)
- Seizure (2)
- cirrhosis (2)
- liver (2)
- portal hypertension (2)
- sphingosine-1-phosphate (2)
- ACLF (1)
- ALL (1)
- AML (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Angiomyolipoma (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Atomic and Molecular Physics (1)
- Bipolar disorder (1)
- Brachiopoda (1)
- Brachiozoa (1)
- Bryozoa (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- CIK cells (1)
- Chirurgie (1)
- Cirrhosis (1)
- Compositional bias (1)
- Consensus (1)
- Costs (1)
- Depression (1)
- Deutsche Gesellschaft für Chirurgie (1)
- Ectoprocta (1)
- Esoterik (1)
- Ethnografie (1)
- Everolimus (1)
- Exoterik (1)
- Feldforschung (1)
- Further education (1)
- G-protein-coupled receptors (1)
- German Society of Surgery (1)
- Goethe, Johann Wolfgang von (1)
- Gαq/11 (1)
- Haploidentical stem cell transplantation (1)
- Hereditary angioedema (1)
- IN-VIVO (1)
- KIR (1)
- Kryptrochozoa (1)
- LOCKED NUCLEIC-ACID (1)
- Liver diseases (1)
- Lophophorata (1)
- MAMMALIAN-CELLS (1)
- MODIFIED OLIGONUCLEOTIDES (1)
- MRP4 (1)
- MTOR inhibitor (1)
- Minimal residual disease (1)
- NSG mice (1)
- Neuroscience (1)
- PASSENGER-STRAND (1)
- PKA (1)
- Pediatric (1)
- Perspective forum (1)
- Perspektivforum (1)
- Phoronida (1)
- Platelets (1)
- Polyzoa (1)
- Portal veins (1)
- Prostaglandin (1)
- Rhabdomyoma (1)
- S1P receptors (1)
- SGPL1 (1)
- SMALL INTERFERING RNA (1)
- SPSS (1)
- STRUCTURAL BASIS (1)
- Simulator (1)
- Sociodemographic characteristics (1)
- Subependymal giant cell astrocytoma (1)
- Surgery (1)
- TSC (1)
- Thrombosis (1)
- Thromboxane (1)
- Veins (1)
- Vergleich der Methodologien (1)
- Weiterbildung (1)
- Zur Farbenlehre (1)
- acute decompensation (1)
- acute leukemia (1)
- acute-on-chronic liver failure (1)
- adenosine receptors (1)
- bile (1)
- brain (1)
- cAMP (1)
- ceramides (1)
- cholesterol (1)
- chromosomal translocations (1)
- comparative methodology (1)
- computed tomography (1)
- cyclooxygenase 2 (1)
- eNPP2 (1)
- ethnography (1)
- field (1)
- field site (1)
- fieldwork (1)
- glioblastoma cells (1)
- hearing loss (1)
- hepatic encephalopathy (1)
- immunotherapy (1)
- inner ear (1)
- leukemia (1)
- mTOR inhibitor (1)
- multi-sited (1)
- nanoparticle (1)
- portosystemic shunt (1)
- preclinical (1)
- renin-angiotensin system (1)
- rhabdomyosarcoma (1)
- rolipram (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- spiral ganglion cell (1)
- spontaneous portosystemic shunt (1)
- translocation partner genes (1)
Institute
A central motivation for the development of x-ray free-electron lasers has been the prospect of time-resolved single-molecule imaging with atomic resolution. Here, we show that x-ray photoelectron diffraction—where a photoelectron emitted after x-ray absorption illuminates the molecular structure from within—can be used to image the increase of the internuclear distance during the x-ray-induced fragmentation of an O2 molecule. By measuring the molecular-frame photoelectron emission patterns for a two-photon sequential K-shell ionization in coincidence with the fragment ions, and by sorting the data as a function of the measured kinetic energy release, we can resolve the elongation of the molecular bond by approximately 1.2 a.u. within the duration of the x-ray pulse. The experiment paves the road toward time-resolved pump-probe photoelectron diffraction imaging at high-repetition-rate x-ray free-electron lasers.
Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
(2019)
Background: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated.
Methods: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein.
Results: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001).
Conclusions: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis.
Trial registration: ClinicalTrials.gov identifier: NCT03584204.
Major mood disorders, which primarily include bipolar disorder and major depressive disorder, are the leading cause of disability worldwide and pose a major challenge in identifying robust risk genes. Here, we present data from independent large-scale clinical data sets (including 29 557 cases and 32 056 controls) revealing brain expressed protocadherin 17 (PCDH17) as a susceptibility gene for major mood disorders. Single-nucleotide polymorphisms (SNPs) spanning the PCDH17 region are significantly associated with major mood disorders; subjects carrying the risk allele showed impaired cognitive abilities, increased vulnerable personality features, decreased amygdala volume and altered amygdala function as compared with non-carriers. The risk allele predicted higher transcriptional levels of PCDH17 mRNA in postmortem brain samples, which is consistent with increased gene expression in patients with bipolar disorder compared with healthy subjects. Further, overexpression of PCDH17 in primary cortical neurons revealed significantly decreased spine density and abnormal dendritic morphology compared with control groups, which again is consistent with the clinical observations of reduced numbers of dendritic spines in the brains of patients with major mood disorders. Given that synaptic spines are dynamic structures which regulate neuronal plasticity and have crucial roles in myriad brain functions, this study reveals a potential underlying biological mechanism of a novel risk gene for major mood disorders involved in synaptic function and related intermediate phenotypes.
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion. They achieved a clinical remission under conventional chemotherapy but relapsed shortly after end of therapy. Both had a history of invasive mycoses (one had possible pulmonary mycosis, one systemic candidiasis). Because no HLA-identical donor was available, a haploidentical transplantation was performed in both cases. Using a specially designed PCR method for the assessment of minimal residual disease (MRD), based on the quantitative detection of the individual chromosomal breakpoint in the MLL gene, all patients achieved complete and persistent molecular remission after transplantation. The immune reconstitution after transplantation is described in terms of total CD3+/CD4+, CD3+/CD8+, CD19+, and CD16+/CD56+ cell numbers over time. The KIR and HLA genotypes of donors and recipients are reported and the possibility of a KIR-mediated alloreactivity is discussed. This report illustrates that haploidentical transplantation may offer a chance of cure without chronic graft-versus-host disease in situations where no suitable HLA-identical donor is available even in a high-risk setting and shows the value of MRD monitoring in the pre- and posttransplant setting.